Current strategies with high-dose tirofiban

Bibliography

• TOPOL EJ, BYZOVA TV, PLOW EF: Platelet GPIIb-IIIa blockers. Lancet (1999) 353(9148):227-231.
   PubMed Web of Science ®Google Scholar
• BOERSMA E, HARRINGTON RA, MOLITERNO DJ et al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 359(9302):189-198.
   PubMed Web of Science ®Google Scholar
• ROFFI M, CHEW DP, MUKHERJEE D et al.: Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur. Heart J. (2002) 23(18):1441-1448.
   PubMed Web of Science ®Google Scholar
• SCHROR K, WEBER AA: Comparative pharmacology of GP IIb/IIIa antagonists. J. Thromb. Thrombolysis (2003) 15(2):71-80.
   PubMed Web of Science ®Google Scholar
• PEERLINCK K, DE LEPELEIRE I, GOLDBERG M et al.: MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation (1993) 88(4 Pt 1):1512-1517.
   PubMed Web of Science ®Google Scholar
• KONDO K, UMEMURA K: Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Clin. Pharmacokinet. (2002) 41(3):187-195.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N. Engl. J. Med. (1998) 338(21):1498-1505.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N. Engl. J. Med. (1998) 338(21):1488-1497.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation (1997) 96(5):1445-1453.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, MOLITERNO DJ, HERRMANN HC et al.: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med. (2001) 344(25):1888-1894.
   PubMed Web of Science ®Google Scholar
• KEREIAKES DJ, KLEIMAN NS, AMBROSE J et al.: Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol (1996) 27(3):536-542.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE D, TOPOL EJ, BERTRAND ME et al.: Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. Eur. Heart J. (2005) 26(23):2524-2528.
   PubMed Web of Science ®Google Scholar
• KABBANI SS, AGGARWAL A, TERRIEN EF et al.: Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am. J. Cardiol. (2002) 89(5):647-650.
   PubMed Web of Science ®Google Scholar
• NEUMANN FJ, HOCHHOLZER W, POGATSA-MURRAY G, SCHOMIG A, GAWAZ M: Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J. Am. Coll. Cardiol. (2001) 37(5):1323-1328.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER DJ, HERRMANN HC, LAKKIS N et al.: Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am. J. Cardiol. (2002) 90(12):1421-1423.
   PubMed Web of Science ®Google Scholar
• ERNST NM, SURYAPRANATA H, MIEDEMA K et al.: Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. (2004) 44(6):1187-1193.
   PubMed Web of Science ®Google Scholar
• DANZI GB, SESANA M, CAPUANO C et al.: Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am. J. Cardiol. (2004) 94(1):35-39.
   PubMed Web of Science ®Google Scholar
• MARDIKAR H, HIREMATH M, MOLITERNO D et al.: Optimal Platelet Inhibition in Patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) Study. Annual Scientific Session American College of Cardiology. New Orleans, USA (March 2007).
   Google Scholar
• DANZI GB, CAPUANO C, SESANA M, BAGLINI R: Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention. Curr. Med. Res. Opin. (2003) 19(1):28-33.
   PubMed Web of Science ®Google Scholar
• DANZI GB, CAPUANO C, SESANA M, BAGLINI R: Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement. Catheter Cardiovasc. Interv. (2004) 61(2):179-184.
   PubMed Web of Science ®Google Scholar
• VALGIMIGLI M, PERCOCO G, BARBIERI D et al.: The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J. Am. Coll. Cardiol. (2004) 44(1):14-19.
   PubMed Web of Science ®Google Scholar
• GUNASEKARA AP, WALTERS DL, ARONEY CN: Comparison of abciximab with ‘high-dose’ tirofiban in patients undergoing percutaneous coronary intervention. Int. J. Cardiol. (2006) 109(1):16-20.
   PubMed Web of Science ®Google Scholar
• BOLOGNESE L, FALSINI G, LIISTRO F et al.: Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J. Am. Coll. Cardiol. (2006) 47(3):522-528.
   PubMed Web of Science ®Google Scholar
• VALGIMIGLI M, PERCOCO G, MALAGUTTI P et al.: Tirofiban and sirolimus-eluting stent versus abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA (2005) 293(17):2109-2117.
   PubMed Web of Science ®Google Scholar
• INVESTIGATORS T: Tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin study. J. Am. Coll. Cardiol. (2007) (In Press).
   Google Scholar
• DAWSON C, MUKHERJEE D, VALGIMIGLI M et al.: Meta-analysis of high-dose single-bolus tirofiban versus abciximab in patients undergoing PCI. American Heart Association Scientific Sessions 2006. Chicago, USA (2006).
   Google Scholar